CME: Pharmacotherapy for Triple-Negative Metastatic Breast Cancer: Therapeutic Updates, Best Practices, and Emerging Therapies
ACCREDITATION EXPIRED: October 27, 2022
Activity Description / Statement of Need:
In this online, self-learning activity:
Over a quarter million women and almost 2,700 men in the U.S. are diagnosed with breast cancer each year, and it is the second leading cause of cancer death in women. The prognosis associated with breast has improved in the last few decades due in larger part to earlier detection. Detection at the loco-regional stage is associated with a five-year overall survival (OS) rate of ≥ 85% in contrast to 27% for distant or metastatic breast cancer (mBC).
This activity has been designed to bring healthcare professionals’ knowledge of the rationale behind treatment of mTNBC up to date and to improve their competence and performance in treating it.
Target Audience:
The following HCPs: medical oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with breast cancer.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: October 27, 2021 -- Expiration Date: October 27, 2022
Faculty: Yuan Yuan, MD, PhD
Agenda
|
Faculty introduction, disclosures |
|
|
Introduction content: cursory refresher and review of mTNBC
|
|
|
mTNBC treatment
· Presence vs. absence of rapidly progressive visceral disease · ± BRCA mutation, ± progression on a PARP inhibitor · ± PD-L1 · Previous chemotherapy exposure · Microsatellite instability-high / mismatch repair-deficient tumors · Later-line therapies
· Emerging therapies · Immunotherapies · PARP inhibitors · PI3K / AKT
· Adverse effect identification and management · Gaps in care
|
|
|
Summary, conclusions, and best practice recap |
|
Learning Objectives
By the end of the session the participant will be able to:
- Describe guideline-recommended therapy for mTNBC
- Recall first- and later-line pharmacotherapies for mTNBC
- Discuss investigational therapies for mTNBC, their mechanisms of action, and their anticipated place in therapy
- List the challenges and barriers to care associated with treating patients with mTNBC
- Formulate a treatment plan for a patient with mTNBC
Accreditation
ACCME Activity #201761696
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure:
Yuan Yuan, M.D., Ph.D., Associate Clinical Professor, Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, has received financial compensation for research and/or consulting from : Pfizer, Merck, Genentech, Eisai, Novartis, Immunomedics, Gilead, Imugene, and AstraZenica.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will not discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by educational grants from Merck and Seagen.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.